Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600211's Forward Dividend Yield % is ranked better than 98.24% of 511
companies
in the Drug Manufacturers industry
Industry Median: 1.99
vs SHSE:600211: 9.04
During the past 12 months, Tibet Rhodiola Pharmaceutical Holding Co's average Dividends Per Share Growth Rate was -10.40% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 93.10% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 39.60% per year.
During the past 10 years, the average Dividends Per Share Growth Rate was 43.00% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Tibet Rhodiola Pharmaceutical Holding Co was 98.80% per year. The lowest was 8.60% per year. And the median was 43.60% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Tibet Rhodiola Pharmaceutical Holding Co Forward Dividend Yield % Related Terms
SHSE:600211 vs ZTS, UTHR: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Rhodiola Pharmaceutical Holding Co's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tibet Rhodiola Pharmaceutical Holding Co Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tibet Rhodiola Pharmaceutical Holding Co's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Tibet Rhodiola Pharmaceutical Holding Co's Forward Dividend Yield % falls into.
Tibet Rhodiola Pharmaceutical Holding Co Forward Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Tibet Rhodiola Pharmaceutical Holding Co Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
CNY 0.876000
2026-05-22
2026-05-21
2026-05-22
Cash Dividend
quarterly
CNY:CNY 1.000000
CNY 0.881000
2025-09-01
2025-08-29
2025-09-01
Cash Dividend
quarterly
CNY:CNY 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Dividend Yield % of 9.04% mean?
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) has a Forward Dividend Yield % of 9.04% as of Jul. 14, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. According to the industry distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #9 out of 511 companies in the Drug Manufacturers industry, placing it in the top 1.8%.
Is Tibet Rhodiola Pharmaceutical Holding Co's Forward Dividend Yield % too high?
Tibet Rhodiola Pharmaceutical Holding Co's current Forward Dividend Yield % is 9.04%. The Drug Manufacturers industry median Forward Dividend Yield % is 1.99. Tibet Rhodiola Pharmaceutical Holding Co's value of 9.04% is 354.3% above this industry median. Based on the distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #9 out of 511 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Tibet Rhodiola Pharmaceutical Holding Co has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tibet Rhodiola Pharmaceutical Holding Co's Forward Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #9 out of 511 companies for Forward Dividend Yield %. This places Tibet Rhodiola Pharmaceutical Holding Co in the top 2% of its industry — outperforming the majority of peers. The industry median Forward Dividend Yield % is 1.99. Tibet Rhodiola Pharmaceutical Holding Co's value of 9.04% is 354.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 1.99, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tibet Rhodiola Pharmaceutical Holding Co's current Forward Dividend Yield % of 9.04% is 354.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 1.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tibet Rhodiola Pharmaceutical Holding Co's current Forward Dividend Yield % is 9.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tibet Rhodiola Pharmaceutical Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) is currently considered Fairly Valued. The stock's GF Value™ is ¥40.53, compared to a current price of ¥39.30 — trading 3% below its estimated fair value. The current Forward Dividend Yield % is 9.04% and 354.3% above the Drug Manufacturers industry median of 1.99. Tibet Rhodiola Pharmaceutical Holding Co's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211), the current Forward Dividend Yield % is 9.04% as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Overvalued in 2026?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co stock appears to be undervalued.
The current stock price of ¥39.30 is trading 3% below its estimated GF Value™ of ¥40.53.
GuruFocus considers Tibet Rhodiola Pharmaceutical Holding Co to be Fairly Valued.
Key valuation signals for SHSE:600211:
Forward Dividend Yield %: 9.04%
GF Value™: ¥40.53 vs. price of ¥39.30 (3% below fair value)
Industry Position: 354.3% above the Drug Manufacturers median (#9 of 511)
No single metric tells the full story. See the SHSE:600211 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tibet Rhodiola Pharmaceutical Holding Co Business Description
Tibet Rhodiola Pharmaceutical Holding Co is a pharmaceutical company engaged in the production and sales of capsules, biological agents, granules, and coatings. The company's products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs, involving fields such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines.
94GF Score
Get the complete analysis for SHSE:600211
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600211 has been successfully added to your 
